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STATISTICAL METHODS FOR TWO PROBLEMS IN CANCER RESEARCH: 
ANALYSIS OF RNA-SEQ DATA FROM ARCHIVAL SAMPLES AND 
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Jialu Li, M.S. 
Advisory Professor: Wenyi Wang, Ph.D. 
 
My dissertation is focused on quantitative methodology development and application 
for two important topics in translational and clinical cancer research. 
The first topic was motivated by the challenge of applying transcriptome sequencing 
(RNA-seq) to formalin-fixation and paraffin-embedding (FFPE) tumor samples for 
reliable diagnostic development. We designed a biospecimen study to directly compare 
gene expression results from different protocols to prepare libraries for RNA-seq from 
human breast cancer tissues, with randomization to fresh-frozen (FF) or FFPE conditions. 
To comprehensively evaluate the FFPE RNA-seq data quality for expression profiling, 
we developed multiple computational methods for assessment, such as the uniformity and 
continuity of coverage, the variance and correlation of overall gene expression, patterns 
of measuring coding sequence expression, phenotypic patterns of gene expression, and 
measurements from representative multi-gene signatures. Our results showed that the 
principle determinant of variance from these protocols was use of exon capture probes, 
followed by the conditions of preservation (FF versus FFPE), then phenotypic differences 
between breast cancers. We also successfully identified one protocol, with RNase H-
based ribosomal RNA (rRNA) depletion, exhibited least variability of gene expression 
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measurements, strongest correlation between FF and FFPE samples, and was generally 
representative of the transcriptome.   
In the second topic, we focused on TP53 penetrance estimation for multiple primary 
cancers (MPC). The study was motivated by the high proportion of MPC patients 
observed in Li-Fraumeni syndrome (LFS) families, but no MPC risk estimates so far have 
been provided for a better clinical management of LFS. To this end, we proposed a 
Bayesian recurrent event model based on a non-homogeneous Poisson process in order to 
estimate a set of penetrance for MPC related to LFS. Toward the associated inference, we 
employed the familywise likelihood that allows for utilizing genetic information inherited 
through the family. The ascertainment bias, which is inevitable in rare disease studies, 
was also properly adjusted by inverse probability weighting scheme. We applied the 
proposed method to the LFS data, a family cohort collected through pediatric sarcoma 
patients at MD Anderson Cancer Center from 1944 to 1982. Both internal and external 
validation studies show that the proposed model provides reliable penetrance estimates 
for MPC in LFS, which, to the best of our knowledge, have never been reported in the 
LFS literatures yet.  
   The research I conducted during my PhD study will be useful to translational 
scientists who want to obtain accurate gene expression by applying RNA-seq technology 
to FFPE tumor tissue samples. This research will also be helpful to genetic counselors or 
genetic epidemiologists who need high-resolution penetrance estimates for primary 
cancer risk assessment.  
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1. Introduction 
1.1 Quality evaluation of formalin-fixed and paraffin-embedding tumor biopsies 
RNA sequencing data 
1.1.1 Using RNA sequencing for expression profiling 
The development of gene expression biomarkers for cancer tissues typically relies on 
high-dimensional technologies to discover transcripts from fresh frozen (FF) samples 
with high quality nucleic acids. Biomarkers that measure strong signals from a few 
transcripts generally translate with customized PCR or hybridization assays, but other 
biomarker indications may require more complicated algorithms involving many 
transcripts from a large set of samples with mature clinical annotations(1). RNA 
sequencing (RNA-seq) is a powerful tool that has been successfully implemented for the 
quantification of whole transcriptome abundance using FF samples(2-4). Compared to 
traditional RNA measurement methods, such as quantitative reverse transcription PCR 
(qRT-PCR) and microarray, RNA-seq can interrogate both pre-defined and novel RNA 
species at a greater dynamic range, allowing a more comprehensive exploration for non-
coding RNA biomarkers. Many previous studies have shown that RNA-seq can generate 
accurate expression profiling comparable to that of microarray, preserve biological 
variability(5), and have performance that is reproducible across laboratories and robust to 
the variation of pre-analytical factors(2, 6-9). These also make RNA-seq a promising 
platform for multigene mRNA signature-based assays with clinical validity(10).  
 
1.1.2 RNA-seq data analysis 
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There are many variations of pipelines for RNA-seq data analysis for expression profiling, 
but no optimal pipeline exists for all RNA experiments(11). The best practices of RNA-
seq data analysis depend on the scientific questions of interest, as well as pre-analytical 
and analytical factors involved in the study. For the comparative analysis of feature 
expression between formalin-fixation and paraffin embedding (FFPE) and FF samples, 
the factors that could influence the choice of RNA-seq data analysis are summarized in 
Figure 1.1. In general, the major steps of RNA-seq data analysis involve read alignment, 
quality control, quantification of feature counts and expression data normalization(11-13). 
For read alignment, different algorithms have been developed so that raw reads can be 
either mapped to the genome reference(14) or transcriptome reference(15). Multiple 
quality checks have been proposed to evaluate the quality of raw reads or of the after-
alignment read coverage(16, 17). The feature counts quantified from read alignment file 
are a biased measurement of the true abundance because of differences in library size and 
feature length. Hence, proper count data normalization is required before performing 
expression-based statistical analysis. Common within-samples normalization methods for 
RNA-seq data include count per million (CPM), fragments per kilobase of exon per 
million reads mapped (FPKM) and transcript per million (TPM) (2, 18, 19). TPM is 
reported as a preferred method as it can adjust for both library size and feature length 
effects, and it is more invariant to the change of mean expressed transcript length(15, 19).      
 
1.1.3 Effects of tumor sample preservation in the clinic on RNA 
In diagnostic pathology, FFPE is the standard method for preserving and storing 
tissue samples. FFPE samples are commonly used for analyzing protein, cell 
! ! 3 
morphology(20), and even DNA(21), but are incompatible for the analysis of RNA, as 
RNA is fragmented and chemically modified caused by FFPE. Multiple factors in FFPE 
procedure can influence the RNA integrity(22). For example, the formalin fixation 
process cross-links nucleic acids and proteins, and modifies the RNA by adding the 
mono-methylol to all four bases(23). The high temperature required for paraffin to 
penetrate the tissue during embedding step, as well as the storage at room temperature, 
facilitate this chemical modification, which leads to RNA degradation over time(22). As 
a result, the RNA extracted from FFPE samples has much lower yield and shorter 
fragment length compared to the high quality RNA extracted from FF samples. 
  Increasing number of studies support that RNA-seq can be used to reliably profile 
FFPE specimens, despite that the RNA derived from FFPE samples is fragmented and 
variably chemically modified. For example, Sinicropi et.al used 5-12 year old FFPE 
tumor sample RNA-seq data to successfully re-discover breast cancer recurrence risk 
RNA biomarkers that were developed based on RT-PCR(24). Adiconis et.al, Li et.al, Liu 
et.al and Graw et.al showed that overall gene expression is highly correlated (r>0.8) 
between FFPE and matched FF RNA-seq data using different types of tumor samples(25-
27). Lin et.al applied RNA-seq to FFPE bladder tumor samples to identify a gene 
signature that can predict the risk of developing non-muscle invasive versus muscle 
invasive tumors for patients with high-grade T1 bladder cancer(28).  
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Figure 1.1: Overview of pre-analytical and analytical factors relevant to the evaluation of 
FFPE sample RNA-seq data quality for expression profiling.  
 
1.1.4 Limitations of previous studies on FFPE samples RNA-seq expression profiling 
quality evaluation  
One major limitation of previous FFPE RNA-seq expression data quality evaluation 
studies is on the experimental design. For example, the reference standards or the “gold-
standards” used for the comparative analysis are usually those generated by mRNA 
sequencing or total RNA sequencing from matched FF samples(24-27). The variation and 
concordance within those FF RNA-seq data generated by different library preparation 
protocols have not been thoroughly evaluated. On the other hand, several library 
preparation protocols designed for FFPE samples, such as rRNA depletion, template 
!
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RNA random amplification, capture sequencing and chemical de-modification, have 
already been tested(10). But none of previous studies has evaluated all of these protocols 
together in one study.    
Another limitation of previous studies is the scope of evaluation metrics used for 
comparative analysis. To be analytically valid, FFPE RNA-seq data must demonstrate 
both reproducibility and accuracy in uncovering intelligent expression signals. For 
example, we expect valid FFPE RNA-seq data not only have high expression 
concordance with match FF references for both genes and coding sequences, but also 
allow us to re-discover true differential expressed genes that we have identified from the 
FF “gold-standards”. We’re also interested in whether we can use FFPE RNA-seq data to 
correctly cluster the tumor sample phenotypes or what are the dominant factors causing 
differences between FFPE and FF RNA-seq data. However, previous studies have no 
comprehensive evaluations based on these criteria.      
 
1.2 Characterization of the onset of multiple primary cancers  
1.2.1 The Li-Fraumeni syndrome data 
Li-Fraumeni syndrome (LFS) is a hereditary cancer syndrome first recognized by 
two physicians, Frederick Pei Li and Joseph F. Fraumeni Jr., after evaluating the medical 
records and death certificates from pediatric sarcoma patients(29). Individuals with LFS 
are characterized with high risk of developing early-onset, multiple and multiple types of 
primary cancers throughout his/her lifetime(30). The syndrome is associated with 
germline mutation in TP53 tumor suppressor gene, and follows an autosomal dominant 
inheritance rule(31, 32). Recent studies have shown that cancer risk in LFS patients is 
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also associated with gender(33) and the interaction effect between TP53 genotype and 
gender(34). 
The data that motivated our study is a family cohort of LFS collected through 
probands with pediatric sarcoma treated at MD Anderson Cancer Center from January 
1944 to December 1982 and their extended relatives. The data was collected based on 
probands with sarcoma diagnosed before age 16 and with at least 3 years after-diagnosis 
survival. The data collection was extended to the probands’ blood relatives, which 
includes the probands’ grandparents, parents, parental siblings, siblings and offspring. 
For each individual, the gender and the diagnoses of any malignant cancer except the 
non-melanoma skin cancer were recorded from the date of birth until the data of death or 
the study termination date, whichever came first. All cancer diagnoses were confirmed by 
medical records and death certificates. The primary cancer diagnoses were determined 
based on the histology and site information recorded for each cancer event. More details 
on inclusion criteria and cancer diagnosis confirmation can be found elsewhere (31, 35). 
We define mutation carrier in this study as someone with missense or truncation 
mutations in exons 2-11 of the TP53 gene tested from peripheral-blood samples. All 
probands were tested for the TP53 mutation status, and once positive, all of their first-
degree relatives and any other family members with a high risk of being mutation carrier 
were also tested. More information about mutation testing can be found elsewhere(33).  
 
1.2.2 Multiple primary cancers and the penetrance 
A primary cancer develops independently at different sites and histology from 
original cancer, which is not caused by extension, recurrence or metastasis(36). Multiple 
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primary cancers (MPC) refer to the case when primary cancers occur more than once per 
subject over the follow-up time. The MPC cases are getting increasingly common due to 
advances of the cancer treatment and related medical technologies. The National Cancer 
Institute estimates that there are around eleven million cancer survivors in the US as of 
2005, which is more than three times than that in 1970(37). Furthermore, surviving a 
cancer does not necessarily suggest a decreasing risk of developing another cancer. For 
example, Eggermond et.al reported that the risk for a second primary among Hodgkin 
lymphoma survivors is 4.7-fold increased compared with that in the general 
population(38). The risk of developing MPC varies by genetic susceptibility factors as 
well. For example, LFS is associated with germline mutation in TP53(39, 40). 
Penetrance is defined as the proportion of individuals with the genetic variants 
(genotype) that cause a particular trait and who have clinical symptoms of the trait 
(phenotype). It plays a crucial role in many genetic epidemiology studies to characterize 
the association of germline mutation with disease outcomes(41). For example, penetrance 
is an essential quantity for disease risk assessment, which is clinically important to 
identify at-risk individuals and to provide prompt disease prevention strategies. To be 
more specific, popular risk assessment models often require the penetrance estimates as 
inputs(42, 43).  
 
1.2.3 Challenges of estimating MPC penetrance using LFS data 
The goal of this study is to estimate MPC-specific penetrance in LFS, which is 
defined as Pr(developing the next primary cancer by age t | Genotype & (Cancer history, 
Gender). It shall therefore lead to more accurate cancer risk assessment in LFS for both 
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cancer survivors and no-cancer-history individuals by utilizing more detailed individual 
cancer histories with MPC.  
Few attempts have been made for taking into account MPC in the penetrance 
estimation. Wang et.al used Bayes' rule to calculate multiple primary Melanoma (MPM)-
specific penetrance, based on penetrance estimates for carriers, the ratio of MPM patients 
for carriers and non-carriers, and the ratio of MPM and single primary Melanoma (SPM) 
patients for carriers(44). However, they do not account for age and other factors that may 
contribute to variations observed in SPM and MPM patients, and rely on previous 
population estimates of penetrance and relative risk. To the best of our knowledge, this is 
the only work that has tried to estimate MPC-specific penetrance. 
We remark that MPC can naturally be regarded as recurrent events which have been 
extensively studied in statistics(45). However, the MPC-specific penetrance estimation 
from the LFS data is more challenging than the conventional recurrent event model due 
to the following reasons.  
First, the majority of individuals (74%) has unknown TP53 genotype in the LFS 
family data. Since the genotypes within a family are highly correlated through the rule of 
Mendelian inheritance, we cannot simply ignore the missing information. Instead, we 
need to consider all possible genotypes for untested individuals, with the probability of 
each inferred genotype calculated based on family structure.  
Second, the rate of cancer occurrence is time-varying and we need to take into 
account for time-dependent covariates like cancer status. To tackle this issue, we exploit 
the non-homogeneous Poisson process (NHPP) with time-varying occurrence rate(45-47). 
One may suggest Andersen-Gill model that extends Cox regression to the recurrent event 
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data context(48, 49). However, it cannot be directly applied to our case since there is no 
clear way to extend the partial likelihood to the family data in which the complicated 
pedigree structure should be taken into account for the estimation.  
Finally, the LFS data are collected through high-risk probands with pediatric 
sarcoma and hence are not random samples. This is often referred to as the ascertainment 
bias, which commonly occurs in rare diseases studies and should be properly corrected 
for an unbiased estimation. 
 
1.3 Dissertation organization 
This dissertation focuses on addressing the two challenges described in above 
sections. In chapter 2, we developed multiple evaluation criteria, accounting for different 
read alignment algorithms and count data normalization methods, to assess the expression 
profiling quality using FFPE tissue samples RNA-seq data, as compared to high quality 
FF references. In this study, we applied RNA-seq, following 6 different RNA-seq library 
preparation protocols, to identical pairs of breast cancer tissue that were randomized to 
FF or FFPE conditions. The parameters we used for evaluation covers post-alignment 
quality checks, read coverage quality, overall data variation, correlation, differential test 
and expression pattern similarity in coding sequences. We identified one RNA-seq library 
preparation protocol with consistent good transcript coverage uniformity and continuity, 
most concordant expression for overall and specific signature genes, and least differential 
expression when compared to the different non-capture sequenced FF samples.   
In chapter 3, we developed a novel statistical model that can estimate the MPC 
penetrance using genotype-incomplete LFS family data. In brief, we consider the MPC 
! ! 10 
occurrence in a randomly selected individual as a Poisson process and build the model 
with the following two major components: 1) Recurrent events modeling, which is 
devised to estimate the time varying hazard that fully characterizes the primary cancer 
occurrence process. We used a proportional hazard function where the baseline is a 
function of current age and the exponential component can incorporate covariates of 
interest. The model can thus consider effects from current age, cancer history or genetic 
factors when estimating the risk for next primary cancer development. 2) Missing 
genotype imputation via the Elston-Stewart algorithm(50), which significantly increases 
the statistical power for parameter estimation using incomplete real data. This approach 
improves computational efficiency by exploiting the Mendelian inheritance property 
when inferring the missing genotype and recursively partitioning the original family into 
nuclear ones. We also correct the ascertainment bias in the model and finally make 
inference on model parameters via the Markov Chain Monte Carlo method. Our method 
shows reasonable cancer risk prediction performance in both internal and external 
validations. 
In chapter 4, we conclude the dissertation with discussion and future research. 
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2. Protocols for transcriptome sequencing of formalin-fixed tumor biopsies that best 
represent high quality frozen tissue   
2.1 Introduction 
While it is generally best to identify gene expression biomarkers from cancer tissues 
using the highest quality of ribonucleic acids (RNA) purified from fresh frozen (FF) 
samples, any subsequent development toward diagnostic testing will require its 
translation for use with formalin-fixed paraffin-embedded (FFPE) tissue samples. 
However, the variably fragmented and chemically modified RNA derived from FFPE 
samples presents a challenge for accurate measurement of gene-expression(23, 51).  
In a different context, there is great interest to perform transcriptome sequencing 
(RNA-seq) for biomarker discovery research using large cohorts of precious archival 
FFPE samples from completed clinical trials. However, an unfavorable signal-to-noise 
ratio from FFPE samples could reduce the accuracy of biomarker discovery. Therefore, it 
is essential to select a protocol for FFPE RNA-seq libraries that yields data that is 
comparable with a “gold standard” result from FF samples. But there is more than one 
standard protocol for RNA-seq of high-quality RNA from FF tumor samples.  
We have summarized different approaches for RNA-seq library preparation in Figure 
2.1. Those include: 1) selection of messenger RNA by targeting the poly(A) 3’ tail 
(mRNA protocol), 2) depletion of more abundant ribosomal RNA (rRNA depletion) 
using bead-based method (I.TotalRNA protocol) or enzymic method (K.TotalRNA 
protocol), and 3) exon capture probes for known coding region sequence (CDS) from an 
RNA-seq library prepared (CR protocol). Data generated from the popular mRNA 
protocol using FF tissue samples (FF.mRNA library) are highly concordant with 
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microarray data in tumor gene expression signature study (8). But this protocol is not 
appropriate for degraded mRNAs from FFPE samples (52). On the other hand, total RNA 
library protocols do not restrict enrichment to poly(A)+ tailed mRNA, allowing less 
biased quantification of isoform abundance (52, 53).  
Corresponding protocols for RNA-seq from FFPE tumor samples include an 
adaptation of the mRNA protocol that combines random and poly(A) primers (sRNA 
protocol) was optimized for gene expression microarrays (SensationPlus kit, Affymetrix, 
CA); or are unchanged for the I.TotalRNA, K.TotalRNA and CR protocols (Figure 2.1). 
Total RNA protocols have achieved Pearson correlations with FF counterparts of >0.9 
(26, 52, 54). Exon capture using the CR protocol has potential for stronger correlation, 
but involves selected coverage(55). Finally, since pre-treatment heat and methyl 
saturation have been claimed to reduce methylol adducts on FFPE RNA, we evaluated 
pre-analytical demethylation (deM) of total RNA prior to library preparation using the 
CR protocol and the sRNA protocols (Figure 2.1).  
Consequently, this study was designed to directly compare the results from RNA-seq 
library protocols between optimally matched sample pairs (FF and FFPE) from 
representative breast cancers, in order to address three scenarios in translational research: 
1) biomarker discovery from FF samples phase with intention to translate for FFPE 
samples in future studies for validation and diagnostic development, 2) biomarker 
discovery from FFPE samples that is intended to be representative had high quality FF 
samples been available, and 3) translation of existing biomarkers, developed using a 
different method (such as microarrays or RNA-seq using mRNA protocol), for use with 
RNA-seq data from FFPE samples.  
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Figure 2.1: Workflows of RNA-seq library preparation. The red color indicates steps only 
applied to FF samples, while the blue indicates steps only applied to FFPE samples. The 
grey shaded boxes contain the names for each protocol. The * indicates different rRNA 
depletion methods that result in two different TotalRNA protocols, that is, RiboZero for 
I.TotalRNA and Rnase H for K.TotalRNA protocol. 
 
 
2.2 Methods 
2.2.1 Tumor tissue samples 
In order to minimize any impact from intratumoral heterogeneity, we collected fresh 
tissue, diced it into pieces of 1-2!! diameter, stirred, and then randomly assigned half to 
RNAlater solution or 10% neutral buffered formalin. The tissue in RNAlater was frozen 
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and stored at -80°C freezer (FF). The tissue in formalin was processed as a FFPE tissue 
block within the Histology and Tissue Processing Facility in MD Anderson Cancer 
Center. The phenotypes of the nine breast cancers, defined by pathologic status of 
hormone receptors (HR) and HER2 receptor were: HR+/HER2- in five, HR+/HER2+ in 
one, and triple receptor-negative (TN) in three (Table 2.1, 2.2). 
 
 
 
 
 
 
 
 
Table 2.1: Summary of starting RNA materials and the related cost for the RNA-seq data 
generated in this study. 
 
 
!
 
Histopathology 
annotation RIN 
 
DV200 
Duration 
of fixation 
(days) 
Cut slides 
Storage 
time (days) 
Tumor ID ER PR HER2 FF FFPE FFPE FFPE FFPE 
C + + - 6.7 1.7 65 2 8 
E + + - 6.7 1.7 79 1 264 
F + + - 6.9 1.6 80 3 242 
N + + - 9.3 1.3 77 3 239 
T + + - 8.2 1.2 80 1 197 
R + + + 6.8 1.9 78 1 155 
G - - - 9.3 2.2 85 1 123 
L - - - 6.9 2.2 76 1 81 
S - - - 7.6 2.0 79 1 66 
Chemistry Procedure Sample 
Size 
Starting 
RNA(!") Cost ($) Time (days) 
FF.mRNA 18 500 75 2 
FF.CR 9 10 160 3 
FF.I.TotalRNA 9 100 120 2 
FF.K.TotalRNA 9 100 105 2 
FFPE.K.TotalRNA 9 100 105 2 
FFPE.I.TotalRNA 9 100 120 2 
FFPE.sRNA 18 100 170 3 
FFPE.CR 9 20 160 3 
FFPE.deM.CR 9 20 160 3 
FFPE.deM.sRNA.CR 9 100 170 3 
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Table 2.2: Histopathology annotation, extracted RNA integrity and sample fixation and 
storage time for FFPE condition of the nine breast tumors. All slides were cut right after 
the block was prepared. All the cut slides were stored at 4°C in sealed cases until they 
were used for RNA extraction.    
 
2.2.2 RNA-seq library construction and sequencing 
The FF RNA was purified from the sample in RNAlater using the RNeasy Mini Kit 
(Qiagen, Valencia, CA), while the FFPE RNA was purified from 10!" freshly-cut 
sections using High Pure FFPE RNA Isolation Kit (Roche, Indianapolis, IN). A DNase-I 
treatment step was included in both the FF and FFPE RNA isolation protocols. RNA 
concentration was quantified using Nanodrop (Nanodrop Technologies, Wilmington, DE), 
and its integrity was assessed using a Bioanalyzer 2100 and an RNA Chip assay (Agilent 
Technologies, Wilmington, DE). 
The mRNA protocol began with poly(A)+ mRNA enrichment on 500!" of total 
RNA using oligo-dT beads followed by standard procedures of TruSeq RNA Sample 
Prep Kit v2 (Illumina, San Diego, CA). Briefly, the poly(A)+ mRNA was fragmented, 
then double-stranded cDNA was synthesized using random primers. After end repair and 
ligation of dsDNA adapters, the library was amplified with 10 cycles of PCR.  
The I.TotalRNA protocol used Ribo-ZeroTM Magnetic Gold Kit to deplete ribosomal 
RNA (rRNA) from 100!" of total RNA, followed by library preparation using the 
Truseq Stranded Total RNA Sample Prep Kit (Illumina, San Diego, CA).  
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The K.TotalRNA protocol used an RNase H-based method to deplete rRNA from 
100!" of total RNA, followed by library preparation using KAPA Stranded RNA-Seq 
Kit with RiboErase (Kapa Biosystems, Wilmington, MA)  
The sRNA protocol began with whole-transcriptome amplification on 100!" of total 
RNA using SensationPlus™ Amplification Kit (Affymetrix, Santa Clara, CA). The 
protocol used the same methods to amplify the RNA template as for gene expression 
microarrays. In brief, the template RNA was reverse-transcribed into the first-strand 
cDNA using random and oligo-dT primers, then the sense RNA (sRNA) was synthesized 
by in vitro transcription. Next, 4.5!" of sRNA was subjected to rRNA depletion using 
the Ribo-ZeroTM Magnetic Gold Kit and then 50!" of rRNA-depleted sRNA was used as 
input for library construction using Truseq RNA Sample Prep Kit v2 as described in 
mRNA protocol, bypassing the poly(A)+ mRNA purification step. 
The Coding-Region (CR) protocol was performed using Truseq Access RNAseq kit 
(Illumina, San Diego, CA) following manufacturer's instruction. In brief, cDNA was 
generated using random primers from the 10!" of RNA from FF, or 20!" of RNA from 
FFPE samples. Next, sequencing adapters were ligated to the resulting cDNA followed 
by the 1st round PCR amplification (15 cycles). After validation, a 4-plex pool of 
libraries was made and the coding regions of the transcriptome were enriched by two 
cycles of hybridization and capture to ensure high specificity. Finally, the 2nd round of 
PCR (10cycles) was performed to further amplify the enriched library for sequencing.  
We also developed a de-modification (deM) protocol to leach methyl adducts from 
FFPE-derived RNA by heating it at 70°C for 30 min in a de-modification solution (1x TE 
buffer containing 20µM NH4Cl, pH7.0) (56)(57). This deM proved effective in restoring 
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the template activity of RNA in RT-PCR (unpublished data). Starting with de-modified 
RNA, we tested three additional FFPE library preparation methods: FFPE.deM.CR, 
FFPE.deM.sRNA.CR, FFPE.deM.sRNA. These methods followed the same main 
protocols mentioned above, with same amount of de-modified FFPE RNA as input. 
In each protocol, the FF RNA was subjected to fragmentation prior to reverse 
transcription and cDNA generation, but no fragmentation was performed on FFPE RNA, 
except in the K.TotalRNA protocol where the FFPE RNA was fragmented at 85°C for 3 
min according to manufacturer’s instructions. For the mRNA and sRNA protocols, the 
libraries were prepared with two technical replicates to test reproducibility.  
The size distribution of RNA-seq libraries was measured to be in the range of 200–
600 bp and peaked around 270 bp using Agilent High Sensitivity DNA kit on a 
Bioanalyzer Libraries were quantified using KAPA Library Quantification Kits (Kapa 
Biosystems, Wilmington, MA) and then paired-end sequenced on Illumina Hi-Seq 2000 
Sequencing System with two or four libraries pooled in one lane. All libraries were 
randomly assigned to a lane (4 per lane) of the Hi-Seq 2000 following a rule that no 
technical replicates could share the same lane. We generated 100 base-paired reads for 
sample C and 50 base-paired reads for the other eight samples for the FF.mRNA and 
FFPE.sRNA protocols. All remaining libraries had 75 base-paired reads.  
 
2.2.3 Sequence alignment, post-alignment statistics and expression quantification 
The computational analysis of RNA-seq data performed in this study can be 
summarized in Figure 2.2. We mapped reads to the human reference genome hg19 using 
Tophat2(14) (v.2.0.4, default parameters and supplying the -G option with GTF 
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annotation file downloaded from UCSC genome browser). The concordant pair alignment 
rate was obtained from the Tophat2 output. For rRNA alignment, we mapped reads to 
manually merged human rRNA references using BWA(58) in paired-end mode as 
previously described(26). Gene-level expression was quantified by htseq-count(59) in the 
"union" mode and using same GTF annotation file for mapping. To quantitate CDS-level 
expression, we first modified the GTF annotation file by adding a new feature ID 
"exon_id" into the attribute. The exon_id concatenates the feature type, start and end 
position and gene id for each row. The number of reads mapped to coding sequence was 
counted by htseq-count ("intersection-nonempty" mode, supplying the -t option with 
"CDS" and the -i option with "exon_id"). 
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Figure 2.2: Overview of main RNA-seq data analysis performed in this study.  
 
We used RNA-SeQC (16) (v.1.1.8 and same genome reference and GTF annotation 
file as that used for Tophat2 alignment), with genomic coordinate-sorted alignment file as 
the input, to calculate the mapping rate for exonic, intronic and intergenic regions, the 
coefficient of variation and the number of gaps in reads coverage. To calculate the 
coefficient of variation, the transcript length was normalized to 100 quantiles and the 
mean coverage signal for each quantile was calculated. The coefficient of variation of a 
transcript was calculated by dividing the standard deviation with the mean read coverage 
for that transcript. A smaller value of coefficient of variation indicates a greater 
uniformity of read coverage. The percentage of gaps (defined as >5 consecutive bases 
without coverage) was calculated by dividing the cumulative gap length by the 
cumulative transcript length. A smaller value of gap percentage indicates a greater 
continuity of read coverage.           
We also mapped reads to the human reference transcriptome using RSEM(15) 
(v.1.2.11, Bowtie v.1.0.0 with default setting, and supplying the rsem-prepare-reference 
with UCSC knownGene transcriptome fasta file, and the rsem-calculate-expression with 
paired end mode). In contrast to Tophat2, RSEM avoids dealing directly with the splicing 
junction problem, by aligning the reads to the transcript reference and making inference 
on the relative abundance of each isoform from a mixture model built based on the RNA-
seq data generative process(15, 18). The relative abundance was further adjusted by the 
effective length of isoform as an expression measure named fragments per kilobase of 
exon per million reads mapped (FPKM). An alternative expression measure, named 
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transcripts per million (TPM), was calculated by normalizing FPKM with the sum of per-
nucleotide relative abundance over all isoforms. TPM is preferred to FPKM in some 
previous studies as it is more invariant to the change of mean expressed transcript 
length(18, 19). 
 
2.2.4 Data analysis 
Genes or CDS targeted by the CR protocol were identified using the manifest file for 
the Nextera Rapid Capture Exome preparation kit (Illumina, San Diego, CA), which 
cover same genes as the Truseq Access RNAseq kit. The poly(A)+ genes were kept by 
filtering out poly(A)- genes as previously reported(60). The resultant 20,381 coding-
region targeted and ploy(A)+ genes were then included for further analysis whenever the 
mRNA and CR protocols are involved. For reproducibility and correlation analysis, the 
gene expression data were normalized to X by either CPM or FPKM or TPM and log 
transformed using the formula !! = !"#!(! + 1).  
A variance stabilizing transformation was applied to the CPM-normalized count data 
based on the empirically estimated functional relation between variance and mean as 
previously described(61). Principal component analysis (PCA) was performed on the 
transformed data using the 'prcomp' function in R after the gene variables were centered 
to zero and scaled to unit variance. A total of 17,395 Poly(A)+ genes targeted by CR and 
with at least 1 normalized counts in five or more samples were included for the analysis. 
A total of 3543 genes with variance greater than 1 across all libraries were included for 
the hierarchical clustering analysis, where Euclidean distance and average linkage criteria 
were used. The ‘pvclust’ R package(62) was used to perform 1000 bootstrap resamples 
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on the clustering, and the bootstrap probability (bp) or the frequency that a cluster 
appears in bootstrap replicates was calculated as a measure of cluster uncertainty.   
For differential gene expression analysis on distinct biological groups, the raw gene-
expression data were normalized by two representative methods, (i) upper-quartile 
(UQ)(63): a global scaling method by the top quantile of the per-sample count 
distribution; and (ii) the trimmed mean of M values (TMM)(64): a global scaling method 
using an empirical estimate of relative RNA production of two samples. The TMM is 
based on the assumption that the majority of genes are not differentially expressed 
between groups. It doubly trims the noisy genes whose expression contributes to the bias 
of log-fold-changes (M values), and normalizes the raw gene count data with the 
weighted mean of adjusted M values, where the weight is the inverse of variance of the M 
values. Only genes with at least 5 reads in two or more samples prepared by one library 
construction method were retained for normalization. This resulted in an average of 
16,810 (sd = 265) genes for further analysis. The relative log expression (RLE) is defined, 
for each gene, as the log ratio of read counts to the median count across all samples. The 
normalized counts were fit into negative binomial GLM for differential expression 
analysis using edgeR(65), with tag-wise dispersion. For receiver operating characteristic 
curves (ROC), either one of FF measures (FF.mRNA, FF.I.TotalRNA, FF.K.TotalRNA 
or FF.CR) was used as the gold standard to define truly differentially expressed genes. 
True positives are defined as genes measured as differentially expressed in both the gold 
standard and any one of other protocols, and the true positive rate (TPR) is defined as the 
number of true positives divided by the number of differentially expressed genes 
identified by the gold standard at a specific threshold. The false positive rate (FPR) is 
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analogously defined as the number of false positives divided by the number of non-
differentially expressed genes according to the gold standard. The genes identifiable in 
every library preparation group were included for ROC. The most strongly differentially 
expressed genes were removed by filtering out genes with adjusted p-values smaller than 
0.01. This resulted in a total ~15,000 genes for the ROC.  
For library preparation method-based differential expression analysis, we used the 
paired design in edgeR to identify genes differentially expressed in response to library 
preparation method compared to the reference group for all nine tumors, adjusting for 
baseline difference between tumors. Only genes with at least 5 reads in five or more 
samples out of all 90 libraries were retained for normalization. This resulted in a total of 
18,177 CR-targeted and poly(A)+ genes for further analysis. All analysis and data 
visualization are performed using R (http://www.r-project.org). 
 
2.2.5 Quantification of CDS-expression pattern dissimilarity 
Let !!"# be the CPM-normalized counts for !th CDS of !th gene in !th sample. We 
define the within-gene relative expression of !th CDS as 
!!"# = ! !!"#!!"#! !
where ! = 1,… ! ,!! !; ! = 1,… ! , ! ; ! = 1,… ! ,!. The pattern dissimilarity score used to 
measure pattern dissimilarity of !th gene between any two samples (i.e. ! = 1 or 2) is 
defined as 
!! = ! |!!"! − !!!"!|!!! !
The mean dissimilarity score between the two samples is then 
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! = ! !!"! − !!!"!!!!! ! !
In our study, we only consider CR-targeted poly(A)+ genes with two or more non-zero 
expressed CDS. This results in an average of 15,670 (!" = 134) genes.  
 
2.3 Results 
RNA extracted from FFPE samples was severely degraded, with RNA integrity 
number (RIN) of 1.2-2.2, versus 6.7-9.3 from FF samples (Table 2.2). All libraries 
generated >49 million raw reads (mean= 113 million, sd= 27 million). 
 
2.3.1 Post-alignment statistics 
We calculated the alignment rate for exonic, intronic, intergenic and all genomic 
regions for all libraries (Figure 2.3 and 2.4). Libraries from protocols that did not include 
exon capture probes (I.TotalRNA, K.TotalRNA, sRNA) had different mapping rates from 
FFPE samples than from FF samples, with the following mean differences: lower for 
exonic (overall mean difference= 0.335, ! < 10!!"), higher for intronic (overall mean 
difference= 0.309, ! < !10!!"), and comparable for intergenic sequence reads. The CR 
protocol (that used exon capture probes) had highly concordant mapping between FF and 
FFPE. Efficiency of rRNA depletion was highest for the CR protocol, followed by 
FFPE.K.TotalR (Figure 2.5). Additionally, the FFPE.sRNA protocol had lowest mapping 
rate for concordant pairs of reads, and least efficient rRNA depletion. Overall, The 
number of genes with read coverage (TPM > 0.1) was slightly higher in FFPE samples 
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than in FF samples for both non-CR and CR protocols (Figure 2.6), consistent with 
another report (27). 
 
Figure 2.3: Summary of concordant pair alignment rate. Each box contains the mapping 
rate from nine tumor samples. The concordant pairs are those aligned with proper 
orientation and distance between the pair. 
 
 
0.
3
0.
4
0.
5
0.
6
0.
7
0.
8
0.
9
Co
nc
or
da
nt
 p
air
 m
ap
pin
g 
ra
te
FF.m
RN
A
FF.I
.Tot
alR
NA
FF.K
.Tot
alR
NA
FF.C
R
FFP
E.I.
Tota
lRN
A
FFP
E.K
.Tot
alR
NA
FFP
E.s
RN
A
FFP
E.d
eM.
CR
FFP
E.C
R
FFP
E.d
eM.
sRN
A.C
R
●
●●
● ●
●
● ●
●
●
● ●
●
●
●
●
●
● ● ●
●
●
●
●
● ●
●
●●●
●
●
●
●●
●
●
●● ●
●
●
●
●
●
●●●
● ●
●●
●
●
●
●
●
●
● ●
●
●
●
● ●●
●
●
● ●● ●
●
●
●
●
● ●● ●
●
●
●
●
●
●
●
●
●
! ! 25 
 
 
Figure 2.4: Summary of exonic, intronic and intergenic region alignment rate of all 
mapped reads. Each box contains the mapping rate from nine tumor samples. 
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Figure 2.5: Summary of rRNA alignment rate. Each box contains the mapping rate from 
nine tumor samples. 
 
Figure 2.6: Summary of number of genes with TPM values greater than 0.1.   
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2.3.2 Uniformity and continuity of read coverage of transcripts  
The uniformity of read coverage, as illustrated in Figure 2.7, was measured by the 
mean coefficient of variation (CV) across the top 1000 highly expressed transcripts, and 
coverage continuity was evaluated through the percentage of gaps without read coverage 
(Figure 2.8 and 2.9). FFPE.I.TotalRNA and FFPE.K.TotalRNA libraries demonstrated 
the most uniform and continuous coverage among protocols for FFPE samples, and were 
equivalent to protocols for FF samples. In contrast, the CR protocol produced non-
uniform coverage, with high percentage of gaps, in both FF and FFPE libraries. The 
FFPE.sRNA protocol also introduced non-uniformity. 
 
Figure 2.7: An illustration of mean read coverage for each normalized base position from 
top 1000 highly expressed transcripts for two libraries from FF sample G. The transcript 
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length is normalized to 100 quantiles and the mean coverage signal for each quantile is 
calculated. The coefficient of variation (in parenthesis) of a sample is the standard 
deviation divided by the mean of mean read coverage for that sample.       
 
 
Figure 2.8: Summary of mean coefficient of variation (cv) of top 1000 highly expressed 
transcripts for all samples. Each box summarizes the mean cv from nine samples for one 
library preparation protocol. A lower cv value indicates better uniformity of read 
coverage.   
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Figure 2.9: Summary of the percentage of gaps of top 1000 highly expressed transcripts 
for all samples. Each box summarizes the percentage from nine samples for one library 
preparation protocol.  
 
2.3.3 Pre-analytical sources of variance 
In RNA-seq studies, the variance across samples usually grows with the mean of 
gene expression (also known as heteroscedasticity), and this can be problematic for 
correctly uncovering the underlying pattern in data using techniques such as distance-
based clustering (66). We therefore applied the variance-stabilizing transformation 
method to approximate the independence between variance and mean (Figure 2.10 and 
Methods). Principal component analysis (PCA) of expression of a total of 20,381 CR 
protocol targeted poly(A)+ genes for all libraries showed that the 38.8% of total variation 
captured by the first two principal components was due to use of exon capture probes 
(CR protocol), 20.6% from the second and third components (effects of FFPE and 
biological differences) (Figure 2.11). Hierarchical clustering results, with high confidence 
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(average bootstrap probability= 0.93), showed that the major tumor phenotypes (HR+ vs. 
HR-) and the source tumor, clustered together with FFPE samples (Figure 2.12).    
 
 
Figure 2.10: Scatter plot of per-gene standard deviation across all 90 libraries, against the 
rank of the mean expression level when with or without between sample normalization 
methods. Both log transformation and the variance stabilizing transformation (vst) can 
approximate variance-mean independence or homoscedasticity. Note that in the figure the 
standard deviation was added with one and then log transformed.    
    
 
Figure 2.11 Scatter plot of the first three principal components for CPM-normalized and 
variance stabilizing transformed counts of 20,381 CR-targeted poly(A)+ genes. Each 
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point corresponds to one of 90 libraries. A) the gray color indicates samples prepared 
with CR and the black for those without CR treatment. A 38.8% of total variation comes 
from CR treatment. B) the gray color indicates FF samples and the black for FFPE 
samples. The symbol shape indicates the different biological group. The biological 
differences and FFPE effects are captured, which accounts for 20.6% of total variation. 
 
2.3.4 Protocols that target mRNA or deplete rRNA 
We performed technical replicates from source RNA for the FF.mRNA and 
FFPE.sRNA protocols in all 9 tumors, with replicate library preparation occurring on 
different days. The raw expression values were scale-normalized by total count and 
transformed to log2 count per million (CPM). Technical replicates were highly correlated 
(Spearman rho ≥ 0.992) for all samples (Figure 2.13).  
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Figure 2.12: Hierarchical clustering of all 90 samples. The bootstrap probability (bp) or 
the frequency that a cluster appears in bootstrap replicates is annotated in blue.  
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Figure 2.13: Summary of spearman’s rho between two replicates using FF.mRNA or 
FFPE.sRNA protocols as a measure of technical reproducibility. 
 
 
We next evaluated which library preparation protocol best represented the gene 
expression measurements that would be obtained from FF libraries. We used MA plots to 
compare, for each gene, the differences in expression between two different FF libraries 
against the average expression in the two libraries from tumor C. The log ratios between 
the two FF libraries for CR targeted genes were centered around zero, with small 
variation across different mean expression levels (Figure 2.14). We then compared two 
types of FFPE library protocols to FF.K.TotalRNA using libraries from tumor C (Figure 
2.14). Although more variable than within-FF libraries, the log ratio values of 
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FFPE.K.TotalRNA were still centered around zero at different mean expression levels. 
However, the log ratio values of FFPE.CR to the FF reference deviated from zero at both 
low and high expression levels. The same patterns were observed for all other tumor 
samples (Figure 2.15-2.17). These observations suggest that the TotalRNA protocols 
produced high-quality FFPE RNA-seq data that was comparable to the FF RNA-seq data.  
The FFPE.K.TotalRNA and FF.K.TotalRNA libraries were highly correlated 
(median rank correlation 0.973 using the TPM measure), significantly higher than 
FF.K.TotalRNA with FF.CR (mean difference = 0.066, ! < 10!!), or any other FFPE 
protocol (lowest mean difference = 0.019, ! = 0.031) (Figure 2.18). Results were similar 
using CPM and FPKM measures (Figure 2.19-2.20). The FFPE.K.TotalRNA also had the 
highest median rank correlation with FF.mRNA and FF.I.TotalRNA, in spite of 
normalization methods used (Figure 2.18-2.20). We did note consistently low correlation 
between FF and FFPE for sample N across all the protocols.  
 
 
Figure 2.14: MA-plot of 20,381 CR targeted poly(A)+ genes for tumor sample C when 
using FF.K.TotalRNA sample C library as the reference. A) MA plot for tumor C 
between FF.K.TotalRNA and FF.I.TotalRNA; B) MA plot for tumor C between 
FF.K.TotalRNA and FFPE.K.TotalRNA; C) MA plot for tumor C between 
A B C
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FF.K.TotalRNA and FFPE.CR. M is the log2-transformed expression of a gene from first 
library divided by that from the second library, while the A is the mean log2-transformed 
expression of the gene. The red curve indicates the locally weighted scatterplot smoother 
(lowess) fitted to the data. 
 
  
 
 
Figure 2.15: MA-plot for FF.I.TotalRNA protocol as compared to FF.K.TotalRNA for 
nine breast tumors. The red curve indicates the lowess smoother fitted to the data.  
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Figure 2.16: MA-plot for FFPE.K.TotalRNA protocol as compared to FF.K.TotalRNA 
for nine breast tumors. The red curve indicates the lowess smoother fitted to the data.  
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Figure 2.17: MA-plot for FFPE.CR protocol as compared to FF.K.TotalRNA for nine 
breast tumors. The red curve indicates the lowess smoother fitted to the data. 
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Figure 2.18. Summary of between-protocol correlation coefficients based on TPM. The 
main title of each figure is the reference protocol used for comparison. Each dot is the 
Spearman rho estimate calculated between the reference library and the library showing 
on the x axis. Each box summarizes the Spearman rho estimates from nine breast tumor 
samples. The gray dot indicates the tumor sample N. 
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Figure 2.19: Summary of between-protocol correlation coefficients based on CPM. The 
main title of each figure is the reference protocol used for comparison. Each dot is the 
Spearman’s rho estimate calculated between the reference library and the library showing 
on the x axis. Each box summarizes the Spearman’s rho estimates from nine breast tumor 
samples. The gray dot indicates the tumor sample N.  
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Figure 2.20: Summary of between-protocol correlation coefficients based on FPKM. The 
main title of each figure is the reference protocol used for comparison. Each dot is the 
Spearman’s rho estimate calculated between the reference library and the library showing 
on the x axis. Each box summarizes the Spearman’s rho estimates from nine breast tumor 
samples. The gray dot indicates the tumor sample N.  
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2.3.5 Protocol with subsequent exon capture  
Subsequent use of exon capture probes after TotalRNA library preparation (CR 
protocol) resulted in a median rank correlation of 0.980 between FF and FFPE, but the 
FF.CR had much lower correlation with non-CR libraries (lowest mean difference = 
0.063, ! < 10!! using TPM) (Figure 2.18 and Table 2.3). Comparing the log ratio values 
across all protocols for FF samples, the CR protocol tended to overly enrich the highly 
expressed genes, and was more likely to not capture low expressed genes (Figure 2.14 
and Figure 2.21-2.23). Pre-analytical approaches to de-modification (deM) of methyol 
adducts from FFPE tissue-derived RNA using heat and amines, or random and dT 
primers for mRNA (sRNA protocol) had little effect on the FFPE.CR protocol (Figure 
2.18 and Table 2.3). Addition of the deM method (FFPE.deM.CR) slightly increased 
concordance of expression but was not statistically significant. Similarly, the sRNA 
method (FFPE.deM.sRNA.CR) slightly increased the concordance of expression but was 
not statistically significant.  
 
!
 
          Reference 
Case 
 
FF.mRNA 
 
FF.I.TotalRNA 
 
FF.K.TotalRNA 
 
FF.CR 
FF.mRNA - - - - 
FF.I.TotalRNA 0.979 / 0.970  - - - 
FF.K.TotalRNA 0.977 / 0.967 0.991 / 0.988 - - 
FF.CR 0.917 / 0.897 0.931 / 0.915 0.923 / 0.908 - 
FFPE.I.TotalRNA 0.940 / 0.927 0.969 / 0.963 0.963 / 0.959 0.933 / 0.911 
FFPE.K.TotalRNA 0.947 / 0.928 0.974 / 0.964 0.980 / 0.973 0.911 / 0.880 
FFPE.sRNA 0.946 / 0.900 0.968 / 0.939 0.968 / 0.942 0.910 / 0.856 
FFPE.deM.CR 0.883 / 0.867 0.908 / 0.891 0.899 / 0.884 0.983 / 0.979 
FFPE.CR 0.888 / 0.872 0.912 / 0.894 0.903 / 0.887 0.983 / 0.980 
FFPE.deM.sRNA.CR 0.897 / 0.871 0.915 / 0.889 0.911 / 0.892 0.974 / 0.965 
! ! 42 
Table 2.3: Summary of the median correlation coefficients using either CPM (left) or 
TPM (right). The highest median for FFPE protocols are highlighted in bold.  
 
 
Figure 2.21: MA-plot for FF.CR protocol as compared to FF.mRNA for nine breast 
tumors. The red curve indicates the lowess smoother fitted to the data.  
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Figure 2.22: MA-plot for FF.CR protocol as compared to FF.I.TotalRNA for nine breast 
tumors. The red curve indicates the lowess smoother fitted to the data.  
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Figure 2.23: MA-plot for FF.CR protocol as compared to FF.K.TotalRNA for nine breast 
tumors. The red curve indicates the lowess smoother fitted to the data.  
 
Further investigating these protocol-induced biases, we looked at the number of 
genes that would be considered as “differentially expressed” or “false positive” (FP), 
when we compared data from different library protocols with those from the FF reference 
standards (Figure 2.24 and 2.25). Fewer FP genes would suggest fewer artifacts 
! ! 45 
introduced by a protocol. FFPE.K.TotalRNA RNA-seq data, among all FFPE data, gave 
the fewest genes with significant expression differences at various p-value thresholds 
using different data normalization methods. In contrast, FF.CR, rather than a FFPE 
protocol, was the most biased method, with 84.2% of all genes identified as significantly 
different in expression from FF.mRNA at an adjusted p-value cutoff of 0.01. Also, there 
were fewer FP genes from FFPE.CR data when compared to FF.CR data, but not when 
either library used a non-CR protocol.  
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Figure 2.24: Number of genes identified to be differentially expressed between a 
reference FF protocol, as shown in the main title for each plot, and one of the other 
library preparation methods. A gene is considered as differentially expressed if its 
adjusted p-value from a test of differential expression is lower than the selected cutoff. 
The data is normalized by UQ method.    
 
 
Figure 2.25: Number of genes identified to be differentially expressed between a 
reference FF protocol, as shown in the main title for each plot, and one of the other 
library preparation methods. A gene is considered as differentially expressed if its 
−6 −5 −4 −3 −2
50
00
10
00
0
15
00
0
FF.mRNA
Cutoff for adjusted p−value (log10)
Nu
m
be
r o
f D
E 
ge
ne
s
FF.I.TotalRNA
FF.K.TotalRNA
FF.CR
FFPE.I.TotalRNA
FFPE.K.TotalRNA
FFPE.sRNA
FFPE.deM.CR
FFPE.CR
FFPE.deM.sRNA.CR
−6 −5 −4 −3 −2
50
00
10
00
0
15
00
0
FF.I.TotalRNA
Cutoff for adjusted p−value (log10)
Nu
m
be
r o
f D
E 
ge
ne
s
FF.mRNA
FF.K.TotalRNA
FF.CR
FFPE.I.TotalRNA
FFPE.K.TotalRNA
FFPE.sRNA
FFPE.deM.CR
FFPE.CR
FFPE.deM.sRNA.CR
−6 −5 −4 −3 −2
50
00
10
00
0
15
00
0
FF.K.TotalRNA
Cutoff for adjusted p−value (log10)
Nu
m
be
r o
f D
E 
ge
ne
s
FF.mRNA
FF.I.TotalRNA
FF.CR
FFPE.I.TotalRNA
FFPE.K.TotalRNA
FFPE.sRNA
FFPE.deM.CR
FFPE.CR
FFPE.deM.sRNA.CR
−6 −5 −4 −3 −2
50
00
10
00
0
15
00
0
FF.CR
Cutoff for adjusted p−value (log10)
Nu
m
be
r o
f D
E 
ge
ne
s
FF.mRNA
FF.I.TotalRNA
FF.K.TotalRNA
FFPE.I.TotalRNA
FFPE.K.TotalRNA
FFPE.sRNA
FFPE.deM.CR
FFPE.CR
FFPE.deM.sRNA.CR
! ! 47 
adjusted p-value from a test of differential expression is lower than the selected cutoff. 
The data is normalized by TMM method.    
 
2.3.6 Pattern dissimilarity in measurement of coding sequence  
 We used a pattern dissimilarity score to measure the differences in expression 
patterns of CDS between library protocols, allowing direct comparison of non-CR and 
CR protocols. A smaller value of the score indicates higher similarity between a protocol 
and a FF reference. The distributions of dissimilarity scores across all genes were similar 
within each protocol, but varied across protocols (Figure 2.26). FFPE.K.TotalRNA had 
the lowest mean dissimilarity score when using FF non-CR libraries as the reference 
(Figure 2.27 and Table 2.4).  
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Figure 2.26: Distribution of dissimilarity score d values for all genes in each sample. 
Tumor samples processed by the same library preparation method are shown in the same 
color. 
 
 
Figure 2.27: Boxplot of mean dissimilarity scores for CR-targeted poly(A)+ genes with 
two or more expressed cds. Each point is the mean dissimilarity score calculated between 
a reference FF protocol, as shown in the main plot title, and one of the other library 
preparation methods. 
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Table 2.4: Summary of the median of mean dissimilarity scores across nine tumor 
samples. The lowest median scores for FFPE protocols are highlighted in bold.  
 
2.3.7 Gene expression patterns associated with tumor phenotype  
We analyzed differential expression (DE) of genes comparing HR+/HER2- and TN 
breast cancers within each protocol. Overall, the normalized data were distributed around 
zero relative log expression, and were clustered by tumor phenotypes in the first two 
principal components. The p-value from DE analysis followed the ideal uniform 
distribution for non-DE genes, with a spike close to zero for the DE genes (Figure 2.28). 
ROC curves represented the sensitivity and specificity of the DE analyses using each FF 
reference as the gold standard. FFPE.K.TotalRNA achieved high and stable area under 
the curve (AUC) (0.921 - 0.933) at different cutoffs set for each FF gold standard, even 
after the strongest DE genes in the gold standards had been filtered out (Figure 2.29-2.32 
and Table 2.5). The best agreement between FFPE protocols and each FF standards was 
as follows: FFPE.sRNA with FF.mRNA, FFPE.K.TotalRNA with both FF.I.TotalRNA 
and FF.K.TotalRNA, and FFPE.CR with FF.CR (Table 2.5).   
!
 
          Reference 
Case 
 
FF.mRNA 
 
FF.I.TotalRNA 
 
FF.K.TotalRNA 
 
FF.CR 
FF.mRNA - - - - 
FF.I.TotalRNA 0.055 - - - 
FF.K.TotalRNA 0.059 0.05 - - 
FF.CR 0.093 0.092 0.095 - 
FFPE.I.TotalRNA 0.074 0.068 0.071 0.09 
FFPE.K.TotalRNA 0.071 0.061 0.058 0.097 
FFPE.sRNA 0.077 0.075 0.077 0.094 
FFPE.deM.CR 0.097 0.095 0.097 0.063 
FFPE.CR 0.096 0.094 0.096 0.062 
FFPE.deM.sRNA.CR 0.104 0.103 0.104 0.077 
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Table 2.5: Summary of median AUC values of between tumor phenotype differential 
expression using either UQ (left) or TMM (right) normalization. The highest median 
AUC values for FFPE protocols are highlighted in bold.  
 
 
 
 
 
 
 
 
 
!
!
      Reference 
Case  
 
FF.mRNA 
 
FF.I.TotalRNA 
 
FF.K.TotalRNA 
 
FF.CR 
FF.mRNA - - - - 
FF.I.TotalRNA 0.977 / 0.975 - - - 
FF.K.TotalRNA 0.977 / 0.976 0.987 / 0.987 - - 
FF.CR 0.963 / 0.962 0.967 / 0.966 0.968 / 0.966 - 
FFPE.I.TotalRNA 0.919 / 0.917 0.929 / 0.923 0.931 / 0.929 0.917 / 0.913 
FFPE.K.TotalRNA 0.921 / 0.918 0.932 / 0.925 0.933 / 0.930 0.910 / 0.907 
FFPE.sRNA 0.926 / 0.923 0.928 / 0.922 0.933 / 0.929 0.904 / 0.901 
FFPE.deM.CR 0.920 / 0.919 0.924 / 0.918 0.929 / 0.925 0.923 / 0.921 
FFPE.CR 0.921 / 0.919 0.924 / 0.918 0.928 / 0.924 0.928 / 0.925 
FFPE.deM.sRNA.CR 0.911 / 0.910 0.912 / 0.907 0.921 / 0.918 0.913 / 0.911 
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Figure 2.28: Relative log expression boxplot, principal component analysis, and p-value 
distribution for ER&PR positive (tumor ID: C, E, F, N, T) and triple negative (tumor ID: 
G, L, S) tumors for each library preparation group. The data were normalized by UQ 
method.  
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Figure 2.29: Between-tumor phenotype differential expression analysis results with 
FF.mRNA as the reference. First row: differential expression analysis results based on 
data normalized by UQ; Second row: differential expression analysis results based on 
data normalized by TMM; Left column: ROC curve for the differential expression 
analysis between ER+/PR+/HER2- and ER-/PR-/HER2- tumor samples. The adjusted p-
value cutoff is 0.10 for gold standard, which is the FF.mRNA measures. AUC for each 
curve is included in the parenthesis in the figure legend. Abbreviations: TPR, true 
positive rate; FPR, false positive rate; Right column: Plot of AUC as a function of cutoff 
values for gold standard. Genes with adjusted p-value smaller than 0.01 in FF.mRNA 
group were removed.  
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Figure 2.30: Between-tumor phenotype differential expression analysis results with 
FF.I.TotalRNA as the reference. First row: differential expression analysis results based 
on data normalized by UQ; Second row: differential expression analysis results based on 
data normalized by TMM; Left column: ROC curve for the differential expression 
analysis between ER+/PR+/HER2- and ER-/PR-/HER2- tumor samples. The adjusted p-
value cutoff is 0.10 for gold standard, which is the FF.I.TotalRNA measures. AUC for 
each curve is included in the parenthesis in the figure legend. Abbreviations: TPR, true 
positive rate; FPR, false positive rate; Right column: Plot of AUC as a function of cutoff 
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values for gold standard. Genes with adjusted p-value smaller than 0.01 in 
FF.I.TotalRNA group were removed.  
 
 
 
Figure 2.31: Between-tumor phenotype differential expression analysis results with 
FF.K.TotalRNA as the reference. First row: differential expression analysis results based 
on data normalized by UQ; Second row: differential expression analysis results based on 
data normalized by TMM; Left column: ROC curve for the differential expression 
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analysis between ER+/PR+/HER2- and ER-/PR-/HER2- tumor samples. The adjusted p-
value cutoff is 0.10 for gold standard, which is the FF.K.TotalRNA measures. AUC for 
each curve is included in the parenthesis in the figure legend. Abbreviations: TPR, true 
positive rate; FPR, false positive rate; Right column: Plot of AUC as a function of cutoff 
values for gold standard. Genes with adjusted p-value smaller than 0.01 in 
FF.K.TotalRNA group were removed. 
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Figure 2.32: Between-tumor phenotype differential expression analysis results with 
FF.CR as the reference. First row: differential expression analysis results based on data 
normalized by UQ; Second row: differential expression analysis results based on data 
normalized by TMM; Left column: ROC curve for the differential expression analysis 
between ER+/PR+/HER2- and ER-/PR-/HER2- tumor samples. The adjusted p-value 
cutoff is 0.10 for gold standard, which is the FF.CR measures. AUC for each curve is 
included in the parenthesis in the figure legend. Abbreviations: TPR, true positive rate; 
FPR, false positive rate; Right column: Plot of AUC as a function of cutoff values for 
gold standard. Genes with adjusted p-value smaller than 0.01 in FF.CR group were 
removed.     
 
2.3.8 Representative gene signatures of prognosis 
We compared 5 published breast cancer gene expression signatures (recurrence score 
(Oncotype DX), PAM50, sensitivity to endocrine therapy (SET) index, mammaprint and 
PI3-kinase index (PI3K)) across the 3 FFPE protocols (I.TotalRNA, K.TotalRNA and 
sRNA) and 3 FF protocols as standards (mRNA, I.totalRNA and K.TotalRNA) (10, 67-
71). Best correlations using FFPE protocols with FF.mRNA (range 0.911 - 0.934) were 
not as strong as with FF.I.TotalRNA (range 0.952 - 0.975) or FF.K.TotalRNA (range 
0.956 - 0.986) protocols (Table 2.6). The FFPE.K.TotalRNA protocol had the highest 
observed Spearman correlation coefficient in 13 of these 15 comparisons.  
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Table 2.6: Summary of the median spearman correlation coefficients across nine tumor 
samples for five signature gene sets. The highest median scores for FFPE protocols are 
highlighted in bold.  
 
2.4 Discussion 
Overall, FFPE RNA-seq data reliably captured transcriptional profiles and 
differences in tumor phenotype-based expression in breast cancer samples, just not quite 
as well as FF RNA-seq data. Principle component analyses demonstrated the following 
order of variables influencing gene expression measurements from RNA-sequencing: i) 
whether the library preparation protocol used exon capture for coding region (CR); ii) 
whether the samples was from FF tissue or FFPE tissue; and iii) the biological phenotype 
of the breast cancer based on hormone receptors and HER2 receptor status (Figure 2.2). 
Generally, we observed small differences in performance between non-CR protocols. 
However, even small differences can have important effects on large-scale genomic data 
for biomarker discovery, validation or subsequent diagnostic development. Nevertheless, 
we identified one protocol, FFPE.K.TotalRNA, with consistently good transcript 
coverage uniformity and continuity; most concordant expression; and least differential 
expression when compared to the different non-CR protocols with fresh tissue. This 
!
 
FF reference mRNA I.TotalRNA K.TotalRNA 
FFPE protocol 
I.Total
RNA 
K.Total
RNA 
sRNA I.Total
RNA 
K.Total
RNA 
sRNA I.Total
RNA 
K.Total
RNA 
sRNA 
Oncotype DX 0.909 0.93 0.934 0.97 0.975 0.96 0.969 0.986 0.974 
PAM50 0.901 0.911 0.901 0.953 0.953 0.937 0.957 0.972 0.954 
SET 0.898 0.911 0.898 0.94 0.96 0.942 0.936 0.968 0.95 
Mammaprint  0.905 0.924 0.921 0.947 0.952 0.95 0.932 0.956 0.936 
PI3K  0.926 0.909 0.912 0.956 0.961 0.953 0.955 0.971 0.954 
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protocol utilized RNase H-based rRNA depletion method and outperformed another 
similar TotalRNA-seq method, which used RiboZero to remove rRNA. It had a 
reasonable requirement of total RNA input (100!") for FFPE samples, which is crucial 
for studies using tumor biopsy samples.  
The first translational research scenario that we posed, in the Background section, 
considered the best pairing of protocols that would enable discovery using FF samples 
with intention to later translate for use with FFPE samples. Overall, we favor the 
K.TotalRNA as consistently best, or close to best performance with FFPE protocols, 
when compared to FF.mRNA, FF.I.TotalRNA or FF.K.TotalRNA as reference FF 
protocols. This interpretation was supported by most parameters that we studied – 
including the quality of read coverage, pattern of coding sequence expression, translation 
of overall or phenotype-related gene expression profiles and prognostic signatures. 
The CR protocols yielded concordant results, but very different from all other (non-
CR) protocols. So a CR protocol used for discovery (FF) would preclude other protocols 
for later translation to FFPE samples (Figures 2, 4). Hence, future application of 
customized assays might also be biased. Also, changes to the population of exon capture 
probes within a commercial kit over time could be a potential risk to this approach. 
The most generalizable results from FFPE samples were obtained using the 
Total.RNA protocols without exon capture. Although similar, the FFPE.K.TotalRNA 
protocol produced slightly stronger results than the FFPE.I.TotalRNA protocol. So for 
our second scenario, we prefer the K.TotalRNA protocol for best representation of the 
transcriptome in FFPE samples utilized for discovery research – aiming to represent the 
transcriptional information that FF samples would have provided.  
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Our third translational research scenario involves the translation of an existing gene 
expression signature that was previously developed using a different method (e.g. 
microarray) or a particular RNA-seq protocol. Again, the FFPE.K.TotalRNA protocol 
had the best performance for total transcriptional profile, coding sequence, phenotypic 
discrimination, and for specific gene expression signatures.  
The formalin fixation process is known to cause cross-linkage between nucleic acids 
and proteins, and mono-methyl addition to the RNA bases(23). Although we tested a 
method of chemical de-modification of total RNA, our results showed negligible effect, 
and argue against the incorporation of this method for RNA-seq of FFPE samples (Figure 
4). However, due to limited tumor sample total RNAs, we did not test the performance of 
potential protocols combining de-modification with sRNA alone or TotalRNA methods.  
The inclusion of random and dT primers (sRNA protocol) to simulate the FF.mRNA 
protocol produced good concordance overall, but introduced non-uniformity and 
discontinuity of read coverage across the transcriptome. So there seems to be no 
advantage to incorporating these innovations for RNA-seq of FFPE samples.  
Limitations to our study include small sample size (although cancers were selected to 
represent biologic diversity), optimally short time to fixation of tissues, and lack of 
generalizability (single institution conditions of tissue processing). Also, the effects of 
long-term storage of FFPE samples could not be tested – but would be expected from a 
completed clinical trial. Also, several of the cases had prolonged storage of cut FFPE 
sections (at 4°C) until RNA purification. This could have compromised the FFPE library 
protocols for this comparison, but can also be viewed as stress-testing the FFPE-derived 
RNA. Notwithstanding these limitations, we believe that the results from this study will 
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be helpful to translational researchers as they consider how to obtain accurate gene 
expression by applying RNA-seq methods to FFPE tumor samples.   
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3. A Bayesian estimation of semiparametric recurrent event model with applications 
to the penetrance estimation of multiple primary cancers in Li-Fraumeni Syndrome  
3.1 Introduction 
In this chapter, we propose a Bayesian semiparametric recurrent event model based 
on NHPP. We define and exploit what we call a familywise likelihood in order to 
maximally utilize the genetic information shared by individuals within the same family. 
In particular, we apply the peeling algorithm(50) to evaluate the familywise likelihood 
with large amount of missing genotype information. The ascertainment-corrected joint 
model(72, 73) is used to correct the ascertainment bias.  
The rest of this paper is organized as follows. In Section 3.2, we introduce the LFS 
family data that motivate this study. In Section 3.3, we provide an explorative analysis for 
the data to give a justification of our approach. In Section 3.4, we propose a 
semiparametric recurrent event model for MPC based on NHPP. In Section 3.5, we 
describe how to construct the familywise likelihood including the acsertainment basis 
correction in a great detail, and the posterior updating scheme via MCMC is given in 
Section 3.6. In Section 3.7, we apply the proposed method to the LFS data and the 
estimated age-at-onset MPC-specific penetrances then follow. We also carry out both 
internal and external validation analysis. Final discussions follow in Section 3.8. 
 
3.2 The Motivating Data 
The pediatric sarcoma cohort data consists of 189 unrelated families, with 17 of them 
being TP53 positive families in which there is at least one TP53 mutation carrier within 
the family (Table 3.1). The TP53 status was determined by PCR of TP53 exonic regions, 
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and once a mutation was identified from the proband, all of his/her first-degree relatives 
and any family members at risk of carrying the mutation were also tested. Among a total 
of 3,706 individuals, 964 (26.0%) of them had TP53 mutation status testing results. The 
age at the diagnosis of each invasive primary tumor for each individual was recorded. 
The follow-up periods for each family ranges from 22-62 years starting from the 
acertainment date of probands. Among 570 (15.4%) individuals with a history of cancer, 
a total of 52 (1.4%) had been diagnosed with more than one primary cancer (Table 3.2). 
In the data, we have approximately equal number of cancer patients or healthy 
individuals for the two genders. Further details on data collection and germline mutation 
testing can be found elsewhere(33, 74).  
 
 
 
 
 
 
 
 
 
Table 3.1: Summary of number of families of LFS data 
 
 
 
 
 
 
 With carriers W/O carriers Total 
Number of families 17 172 189 
Number of individuals 2,409 1,297 3,706 
Average family size 141.71 7.54 19.61 
! ! 63 
 
 
Table 3.2: Number of primary cancer patients in LFS data  
  
3.3 Preliminary Analysis of the LFS Data  
Let !!, ! = 1,2,⋯ ,! denotes the age of the !th primary cancer-onset (i.e., the age 
of diagnosis of !th primary cancer), and !! = !!! − !!!! denote the !th gap time 
between two adjacent primary cancers with !! = 0. A common issue in serial gap time 
analysis is that the censoring time, although independent of !!, is depenent of !! if gap 
times are associated with each other(75). The dependent censoring makes it inappropriate 
to fit marginal models for !th gap times !!(! ≥ 2). For example, Cook et.al shows that 
ignoring dependent censoring can lead to underestimation of the survival functions of 
second and subsequent gap times(45). We therefore use the inverse probability of 
censoring weighted (IPCW) estimates of Kendall’s ! to assess the association between !! and !! in the LFS data after adjusting the induced dependent censoring issue(76). 
Number of primaries Gender Wildtype Mutation Unknown 
0 Male 295 9 1276 
 Female 341 8 1207 
1 Male 105 25 139 
 Female 121 23 105 
2 Male 3 9 8 
 Female 3 12 5 
3 Male 0 3 0 
 Female 0 2 2 
4 Male 0 2 0 
 Female 0 1 0 
5 Male 0 0 0 
 Female 0 1 0 
7 Male 0 0 0 
 Female 0 1 0 
Total number of individuals  868 96 2742 
Total number of cancer patients  232 79 259 
Total number of MPC patients  6 31 15 
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We compute the Kendall’s ! using data without those from probands as these individuals 
are not randomly selected for genotype testing (detailed computation can be found in 
Appendix A). The estimated IPCW Kendall’s ! = −0.017 (Jackknife se= 0.005), which 
indicates a very weak negative but statistically significant correlation between the two 
gap times within subjects.  
Figure 3.1 shows Kaplan-Meier estimates of survival functions !! ! = !Pr!(!! > !) 
and !! ! = !Pr!(!! > !), stratified by genotype. The risk set used for calculating !! !  
considers only single and multiple primary patients starting from the first cancer, while !! !  includes all individuals. For both of the TP53 mutation carriers and non-carriers or 
untested individuals, the lengths of the first and the second gap time are not identically 
distributed, with the first gap time significantly longer than the second one. This suggests 
a time trend in the process where the rate of event occurrence would increase with aging. 
Moreover, the mutation carriers appear to have different length distribution from 
wildtype and untested individuals. This empirical difference in successive survival again 
suggests the importance of providing subgroup-specifc and MPC-specific penetrance.  
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Figure 3.1: Kaplan-Meier estimates of survival distribution for the first (!!) or the 
second (!!) gap times after removing data from probands. The dashed lines are the 95% 
confidence bounds of the estimated survival function. Log rank test gave a p-value of < 
10−7 either comparing the first and second gap time distribution for individuals with no 
mutations or unknown genotype of TP53 (Others group), or comparing the first and 
second gap time distribution for individuals with a mutation in TP53 (Mutation group).  
 
3.4 The Model 
3.4.1 MPC-specific age-at-onset penetrance 
The MPC-specific age-at-onset penetrance can be written as  
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(3.4.1)     !"!(!! ≤ !!|!!!!!,!) 
where ! denotes a vector of covariates. In particular, we set !! = (!, !,!×!,!,!×!), 
where ! and ! denotes individual’s genotype (0 for wildtype, 1 for TP53 mutation), 
gender (0 for female, 1 for male), respectively, and ! is one’s cancer status at a specific 
age. Notice that ! is a periodically fixed covariate during follow-up of an individual as its 
value will change at the age of cancer diagnosis. For example, let !! and ! denote the 
observed age of the first cancer onset and censoring time, respectively, then ! is given by 
    ! = 0, ! ∈ [0, !!)!!!!1, ! ∈ [!!, !)  
 
3.4.2 Semiparametric Recurrent Event Model for MPC 
There are two canonical approaches in modeling recurrent events: one approach 
models the event counts via counting process and another approach models gap times via 
renewal process. We will use NHPP for our modeling because of its flexibility in dealing 
with our primary cancer data.  
The NHPP-based approach directly models the number of primary cancers occurred 
by age ! denoted by !(!). The rate function of !(!) that characterizes the counting 
process !{! ! , ! ≥ 0}  is the probability of events occurring at time !, and is defined as  
(4.2)  
! ! = ! lim∆!→!!" ! ! + ∆t − ! ! > 0∆t  
Note that under Poisson process, the rate function is equivalent to the intensity function 
defined as  
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(4.3) 
! ! = ! lim∆!→!!" ! ! + ∆t − ! ! > 0|! (!)∆t  
where !(!) is the event history up to time ! (45, 77). In particular, the NHPP assumes 
that N (t) for a given t follows a Poisson distribution:  
(4.4) !" ! ! = ! = !!(!)!!! !!!(!),      ! = 0,1,2,⋯ 
where Λ(!) is a cumulative rate function defined as  
Λ ! = ! ! !"!!  
Notice that if ! ! = !!, NHPP becomes the homogeneous Poisson process.  
Incorporating the covariates !, we consider the following multiplicative model for 
the conditional rate function given ! denoted by ! !|! :  
(4.5) ! !|! = !!! ! exp!(!!!) 
where !! !  is a baseline rate function, ! denotes the regression coefficient parameter 
vector associated with the covariate !.  
We assume that !! ∈ ! [0,1] without loss of generality. Toward modeling the baseline 
rate function !! ! , we propose a nonparametric model for the cumulative baseline rate 
function Λ! ! = !! ! !"!!  via Bernstein polynomials. To be more precise, we 
approximate Λ! !  by Bernstein polynomials of degree ! (78-80) as follows:  
(4.6) 
Λ! ! ≈ !! !!!!!! !!(1− !)!!! 
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where !! = Λ! !!  and !! !≤ !⋯ !≤ !!! to ensure Λ! !  monotone increasing. 
 Introducing the following transformation of !! = !! and !! = !! − !!!!! for ! = 2,⋯ ,!, (4.6) can be equivalently rewritten as a linear function of !! = !!,⋯ , !!  
(4.7) Λ! ! ≈ !!! !(!) 
subject to !! ≥ 0, ! = 1,⋯ ,!. Here !! ! = (!! !, 1 ,⋯ ,!! !,! ! denotes the 
beta distribution function with parameters ! and ! −! + 1 evaluated at t (81). The 
baseline rate function !! !  is then given by  
(4.8) λ ! ≈ !!!!!(!) 
where !!(!)! = (!!! !, 1 ,⋯ , !!!(!,!)) denotes the beta density with parameters ! 
and ! −!+1 evaluated at t. Finally, we have  
(4.9) ! !|! = !!!!!!(!)exp!(!!!) 
For the value of !, a large ! provides more flexibility to model the shape of baseline 
rate function, but at the cost of increasing computations. We set ! = 5 as this works well 
in most studies(82).  
Finally, the MPC-specific age-at-onset penetrance (4.1) is obtained by 
(4.10) 
Pr !! ≤ !! !!!! = !!!!,!) = 1− exp! − !!!!!(!)exp!(!!!)!"!!!!!!!!!!  
since Pr !! > !! !!!! = !!!!,!) = exp! − λ !|! !"!!!!!!!!!!  
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3.5 Computing Likelihood  
In this work, computing likelihood is not trivial due to a large number of missing 
genotypes and and the ascertainment bias. In this section we define a familywise 
likelihood and propose a way to correct the ascertainment bias.  
Let !!" and !!" denote the censoring time and the total number of primary cancers 
developed for individual ! = 1,⋯ ,!! from family ! = 1,⋯ , !, respectively. Suppose we 
are given a set of data (!!", !!" ,!!") where !!"! = (!!",!:!! = 1,⋯ ,!!"), and !!"! =(!!" , !!" ,!!"×!!" , !!" ,!!"×!!")!are observed covariates for !th individual. Note that !!",! = !!! if the individual has not developed a primary cancer when being censored.  
 
3.5.1 Individual likelihood  
Let !!",! = 0 and !!" ≥ !!",!!", the likelihood contribution of the !th event since (! − 1)th 
event is  
(5.1)  
! !!",! exp! − λ ! !"!!",!!!",!!!  
where !(∙) in the integrand denotes the rate function with fixed covariates !!",! for any 
time points in [!!",!!!, !!",!), during which the covariate !!" is time-invariant. Note the !(∙) is still time-varying within this time interval. See Cook et.al for more details on the 
derivation(45). We show that the likelihood of the !th individual of the !th family with 
primary cancer events at !!", denoted by !!"(!), is given by  
(5.2) 
! ! 70 
!!" ! ∝ !(!!",!)!!"!!! !"# − !(!)!"!!",!!!",!!!
!!"
!!! !"# − !!!"(!)!"!!"!!", !"  
where the covariate !!" in !!!"(∙) is the cancer status within the time interval [!!",!!" , !!"). 
In our model, the full likelihood is extended by considering each event for each 
individual as one term of the likelihood in order to incorporate the periodically fixed 
covariates.  
 
3.5.2 Familywise Likelihood  
Assume data from different processes are independent given covariates, the likelihood for 
the !th family is given by  
(5.3)  
!! ! = !!"!!!!! (!) 
This likelihood construction assumes that the covariates !!" are observed for every 
individual. However, in LFS data, most individuals have their TP53 mutation status 
untested. Let !! = !!,!"#,!!,!"#  and ℎ! denotes the TP53 genotype vector and cancer 
phenotype data (eg: cancer status and age of cancer diagnosis), respectively, for the !th 
family. For simplicity, we denote the ith family likelihood !!(!) as !!(!!|!!). By the law 
of total probability, the likelihood for the observed data is  
(5.4)  !! !! !!,!"# = Pr! !!,!!,!"#|!!,!"#!!,!"#∈!  
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where ! is a set of all possible values of genotypes !!,!"# conditional on !!,!"#. Because 
the set ! increases exponentially with the number of individuals with missing genotype, 
we use Elston-Stewart’s peeling algorithm to recursively calculate !! !! !!,!"#  (50, 83, 
84). The algorithm proceeds by “peeling” out nuclear families from the whole family and 
its computational complexity is approximately linear in the number of individuals with 
unknown genotype. A simple example of how the algorithm can improve the efficiency 
of likelihood calculation is given in the Appendix B. The likelihood for ! independent 
families is then  
(5.5) 
! ! = !! !!|!!,!"#!!!!  
 
3.5.3 Ascertainment bias correction  
The ascertainment bias exists in rare disease studies like LFS study because the data were 
collected from a high-risk population. The familywise likelihood (5.5) we construct is 
then a biased one for the LFS data. To estimate penetrances for a general population, we 
will need to correct for the ascertainment bias.  
 
Let indicator variable !! = 1 denotes that the !th family is ascertained, and !! = 0 
otherwise. !! is a subset variable of ℎ!. When !" !! = 1  is independent of family 
history, we can assume no ascertainment bias. However, in the dataset with ascertainment 
bias, we estimate !" !! = 1|!!,!  from the data. We use ascertainment-corrected joint 
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model to correct the bias(72, 73). Ascertainment bias of !th familywise likelihood is 
corrected by inverse weighting of the probability that !th family is ascertained  
(5.6) 
!" !!|!! = 1,!!,!!,! ∝ !" !!|!!,!!,!!" !! = 1|!!!,!  
Assuming j = 1 in each family is the proband, the weight can be calculated as,  
(5.7) 
!" !! = 1|!!!,! = ! !" !! = 1|!!!" !" !!"|!!!,!!!!  
Because in the LFS data, we ascertained a family by the fact the proband was diagnosed 
with a primary cancer. The weight can be rewritten as,  
(5.8) 
!" !! = 1|!!!,! = ! !" ℎ!!|!!!,!!,! !" !!"!!!∈{!,!}  
where !" ℎ!!|!!!,!!,!  is the data likelihood for the proband. The prob- ability of 
genotype !" !!!  can be calculated based on the mutated al- lele frequency !!. In the 
case of autosomal dominant inheritance disease, !" !!! = 0 = (1− !!)! and !" !!! = 1 = (1− !!)!. The ascertainment bias-corrected familywise likelihood in our 
study is then given by  
(5.9) 
! ! 73 
! ! = !! !!|!!,!"#,!!,!!" !! = 1|!!!,!!!!! ! 
 
3.6 Posterior Sampling through MCMC  
Let !" !  denotes the prior distribution of !, our goal is to estimate ! from the posterior 
distribution, which is given by  
(6.1) !" !|! ∝ !" ! !" !|!  
We set an independent normal prior for ! where !~!!(0,!!), and ! = 100 for vague 
priors. We assign noninformative flat priors for !. We use a random-walk Metropolis-
Hastings algorithm within Gibbs to generate 50,000 posterior estimates in total with first 
5,000 as burn-in.  
 
3.7 Case Study  
We applied our method to the LFS data (Section 3.2, 3.3) and estimated the parameters 
using the MCMC algorithm as described in Section 3.6. We performed a cross-validation, 
in which we compared our prediction of a 5-year risk for developing the next cancer 
given cancer history and genotype information for an individual with the observed 
outcome, based on our penetrance estimates. We also compared our penetrance results 
with population estimates and previous studies on TP53 penetrance.  
3.7.1 Model fitting 
We fit our model to the LFS data up to the second cancer event due to limited number of 
individuals with third or more cancers in this dataset (Table 3.2). Our model contains 
! ! 74 
three relevant covariates including genotype (!), gender (!) and cancer status (!). We 
also include two interaction effects on genotype. The mutated allele frequency !! is set 
as !! = 0.0001 in this study. Sensitivity prior analysis of the Bayesian estimation shows 
that the posterior parameter estimates are insensitive to the setting of ! prior distributions 
or hyper-parameters.  
 
3.7.2 Cancer risk prediction 
3.7.2.1 Internal validation 
We assessed our model in cancer risk prediction using a 10-fold cross-validation. We 
randomly split the 189 families into 10 portions. Our model was repeatedly fit to the 9 
portions of all families to estimate the penetrance, based on which we made prediction 
using remaining 1 portion of the data. The individuals used for prediction are those who 
have known genotype information. We removed the probands because they were not 
randomly selected for genotype testing. We rolled back five years from the age of 
diagnosis of cancer or the censoring age. Based on the rolled-back time, we then 
calculated a 5-year cumulative cancer risk. We made two types of risk prediction that are 
of clinical interests. In the first scenario, we predicted the 5-year risk of developing a 
cancer given that the individual has no history of cancer (affected versus unaffected). In 
the second scenario, we predicted the risk of developing next cancer when the individual 
already developed a cancer before (MPC versus SPC). We combined the results from 
these 10-fold of cross-validation together and evaluated them using the receiver operating 
characteristic (ROC) curves. To assess the variation of prediction caused by data partition, 
we performed 25 times of the random splits for cross-validation. Figure 3.2 shows the 
! ! 75 
results on risk prediction from each random split. The median area under the curve (AUC) 
is 0.810 for predicting the status of being affected by cancer over healthy status, given 
that the individual has no cancer before. The median AUC is 0.706 for predicting the 
status of next cancer when the subject has a history of cancer. The validation performance 
is robust to random splits.  
 
Figure 3.2. ROC of 5-year risk of developing next primary cancer assessed by 10-fold 
cross-validation. The dotted lines are the ROC curves generated from 25 times of random 
splits of the data for cross-validation, and the solid line is the one with median AUC 
value. Sample size: n(Affected)=123, n(Unaffected)=643, n(MPC)=21, n(SPC)=33. 
Abbreviation: se, standard error. 
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3.7.2.2 External validation 
We used the MD Anderson prospective data, collected independently from the model 
training data, for model prediction performance validation. These data have the same 
inclusion criteria, cancer diagnosis confirmation, mutation testing method as that for MD 
Anderson pediatric data. The number of primary cancers in this data is summarized in 
Table 3.3. We only used the individuals with available genotype information for 
validation purpose. 
 
 
 
 
 
Table 3.3: Number of primary cancer patients by the TP53 mutation status and gender in 
MD Anderson prospective data. Abbreviations: SPC, single primary cancer patients; 
MPC, multiple primary cancer patients.    
 
We evaluated the model prediction performance on primary cancer risk using the 
average annual risk computed using our penetrance estimates. The risk was calculated as 
the cumulative probability of developing next primary cancer divided by the follow-up 
time. The receiver operating characteristic (ROC) curve was used to evaluate the 
sensitivity and specificity of predicting a primary cancer incidence using the estimated 
risk probability at various cutoffs. Such model discrimination evaluation method has also 
been used for pancreatic cancer risk prediction in a previous study(85). For Kaplan-Meier 
  Wildtype Mutation 
Healthy individuals Male 95 27 
 Female 115 21 
SPC Male 56 30 
 Female 116 62 
MPC Male 35 35 
 Female 112 70 
Total number of individuals  529 245 
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(KM) method-based risk prediction, we obtained KM survival functions for the time from 
date of birth to first primary cancer, and the time from first primary cancer diagnosis age 
to second primary cancer diagnosis age, respectively. These survival probabilities were 
then converted to penetrance estimate to compute the average annual risk. We used 
Jackknife to compute the standard error of prediction performance(86, 87). In brief, each 
subsample was generated by omitting the !th family and the AUC was calculated for this 
subsample as previously described. The standard error (se) was calculated using the 
Jackknife technique  
!"!"#$$%&'( = ! ! − 1! !"#! − !"# !!!  
where ! is the number of families, and !"# is the mean estimate of AUC values among 
all Jackknife subsamples. As shown in Figure 3.3, our model achieves better performance 
compared to that of KM method for predicting either the first primary cancer (AUC: 
0.754 vs. 0.698) or the second primary cancer (AUC: 0.731 vs. 0.658).     
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Figure 3.3: Comparison of validation performance between our multiple primary cancer-
specific penetrance and those estimated from Kaplan-Meier (KM) method in predicting 
the first or the second primary cancer occurrence using the MD Anderson prospective 
data. Sample size: n(Affected)=98, n(Unaffected)=248, n(MPC)=38, n(SPC)=60. 
Standard error: se(Affected vs. Unaffected)= 0.028, se(Affected vs. Unaffected (KM) )= 
0.032, se(MPC vs. SPC)= 0.046, se(MPC vs. SPC(KM))= 0.055.     
 
3.7.3 The MPC penetrance estimates  
We applied the proposed method to the entire pediatric sarcoma cohort dataset to obtain 
penetrance estimates for single and multiple primary cancers given mutation status in 
TP53. We used Bayesian information criterion (BIC) for model selection. Table 3.3 
0.0 0.2 0.4 0.6 0.8 1.0
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
False Positive Rate
Tr
ue
 P
os
itiv
e 
Ra
te
Affected vs. Unaffected (AUC=0.754)
Affected vs. Unaffected (KM) (AUC=0.698)
MPC vs. SPC (AUC=0.731)
MPC vs. SPC (KM) (AUC=0.658)
! ! 79 
shows that two models have best goodness-of-fit to the data. We decided to use the model 
with the interaction effect on gender !×! as it has been reported that gender has different 
effects on cancer risk for mutation carriers and non-carriers(33). All posterior estimates 
of the model generated from MCMC converged well and had reasonable acceptance 
ratios. The summary of posterior estimates is shown in Table 3.4. The genotype has 
dominant effects on increasing cancer risk, both through main effect and interaction with 
the cancer history, as expected from the exploratory analysis (Section 3.3). Figure 3.4 
illustrates the age-at-onset penetrance for a female and male individual over all ages with 
specified cancer history and mutation status. 
 
 
 
 
 
 
 
 
 
 
Table 3.4 Summary of BIC for model selection 
 
 
 
Table 3.5 Summary of posterior estimates. Abbreviations: sd, standard deviation; AR, 
acceptance ratio.  
 
Model BIC {!, !,!} 2807 {!, !,!,!×!} 2805 {!, !,!,!×!} 2800 {!, !,!,!×!,!×!} 2800 {!, !,!,!×!,!×!, !×!} 2807 
Coefficient Median sd 95% CI AR !!  3.016 3.016 (2.618, 3.391) 3.016 !! 0.298 0.298 (0.024, 0.573) 0.298 !!×! -0.721 -0.721 (-1.220, -0.183) -0.721 !!  -1.765 -1.765 (-2.949, -0.713) -1.765 !!×!   2.117 2.117 (1.006, 3.340) 2.117 
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Figure 3.4: Age-at-onset penetrance for females or males without a history of cancer. The 
shaded area is the 95% credible bands.  
 
 For the second primary cancer risk, our penetrance estimates show that having a 
primary cancer developed before could have a positive effect on increasing cancer 
occurrence rate for mutation carriers but not for non-carriers (Table 3.5), with a hazard 
ratio of !"#!.!!" = 8.3. The second primary cancer risk is also associated with the age of 
first primary cancer diagnosis, with a higher cancer risk for older first primary cancer 
diagnosis age (Figure 3.5 and Table 3.6).   
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Figure 3.5: Penetrance estimates of the second primary cancer since the first primary 
cancer diagnosis time, stratified by the first primary cancer diagnosis time and gender, for 
A) TP53 mutation carriers and B) non-carriers. Each curve represents the median 
penetrance estimates among all penetrance estimates in the first primary cancer diagnosis 
time group. The figures only show penetrance estimates up to age 80. Note that the two 
figures have different y-axis scales.  
 
 
 
 
 
Table 3.6: Median second primary cancer-free times since the first primary cancer 
diagnosis age and their 95% confidence intervals (in parenthesis) estimated for TP53 
mutation carriers, stratified by gender and first primary cancer diagnosis age.    
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3.7.4 Comparison with penetrance estimates from literature  
Figure 3.4 compares penetrance estimates at different ages for females and males, 
stratified by genotype, respectively. As expected, TP53 mutation has a clear effect on the 
increase of cancer risk, especially when the individual has a recent history of cancer. For 
a wildtype subject, a history of cancer does not have positive effect on increasing the risk 
of developing a subsequent cancer.  
Wu et.al estimated TP53 penetrance from six pediatric sarcoma families for both 
mutation carriers and non-carriers(34). This estimate can be considered as a weighted 
average of probability for SPC and MPC patients. Figure 3.4 shows that, for mutation 
carriers, this age-at-onset TP53 penetrance estimate lies between those from cancer 
survivors and non- cancer survivors, as it should be. For non-carriers, the previous 
estimates are very slightly lower than our estimates for individuals without cancer history, 
but higher than those with early age at first diagnosis. When comparing with population 
estimates from Surveillance, Epidemiology, and End (SEER) Results program(88), our 
estimates for non-carriers overlap with the SEER estimate.  
  
 
 
! ! 83 
 
Figure 3.6: Age-at-onset penetrance when with or without a history of cancer for (a) 
female mutation carriers, (b) male mutation carriers, (c) female mutation non-carriers and 
(d) male mutation non-carriers. The shaded area is the 95% credible bands. 
 
3.8 Discussions  
To our knowledge, this is the first attempt to estimate MPC-specific penetrance for 
germline mutation in TP53 with a large amount of missing genotype information in 
individuals that are genetically related. We developed a novel NHPP incorporated with 
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male mutation non-carriers. The shaded area is the 95% credible bands.
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familywise likelihood so that it can model MPC events in the family context, while 
properly accounting for age effect and time-varying cancer status. A Bayesian framework 
was applied to estimate unknown parameters in the model. We also adjusted for 
ascertainment bias in the likelihood calculation so our penetrance estimates can be 
compared to those generated from the general population. Our new method provides a 
flexible framework for the penetrance estimation of MPC data, and shows reasonable 
predictive performance of cancer risk. As the number of multiple primary cancer patients 
becomes increasing in the general population, our method will be useful for prediction 
and clinical management of such diseases.  
We are still left with a few possible extensions. First, we restricted our analysis up to 
the second primary cancer because of limited power in LFS data for the wildtype and 
untested groups. This makes our penetrance estimation unsuitable for individuals with a 
history of two or more cancers. It is straightforward to extend our model to account for 
three or more cancers if we have such cases for each subpopulation.  
Second, the occurrence of primary cancers may be dependent on other factors such 
as cancer treatment. For example, radiotherapy can damage normal cells in tumor 
adjacent area and is associated with excess incidence of solid cancers(89). Our model can 
include additional covariates, as we set for cancer history, to adjust for such dependency 
between successive events.  
Third, because the correlation between first two gap times in the real data is very 
small, the recurrent events model we used in this study does not explicitly consider such 
association. For future datasets that do exhibit a stronger level of correlation between gap 
times, it would be expected the prediction performance of second or subsequent primary 
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cancers can be improved by properly utilizing such correlation information. We note that 
Bayesian parametric copula models have been developed for sequential gap time 
analyses(90). It will be interesting to incorporate such methods into our Bayesian 
framework to deal with missing genotype and ascertainment bias for a more flexible and 
accurate penetrance estimation. However, this is beyond the scope of this study.  
Finally, in MPC studies, there usually exist multiple types of cancers. For example, 
the LFS is characterized by several cancer types such as sarcoma, breast cancer and lung 
cancer. MPC patients are then under the competing risk of multiple type of cancers. In 
our current model, we assume all cancers are of the same type and do not take into 
account of this nontrivial competing risk. Future work may focus on extending our 
methodology to provide a MPC-specific and cancer-specific penetrance estimation.  
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4. Conclusions and Future Research 
4.1 Conclusions 
In this dissertation, we developed statistics and bioinformatics methods to 
specifically solve two important problems in cancer research. The first problem is on 
assessing the accuracy of using FFPE RNA-seq data for gene expression profiling. To 
this end, we designed a FFPE breast tumor biopsies study, with matched high-quality FF 
samples as the reference standards for comparison. We devised multiple computational 
evaluation criteria, which cover almost all major parameters relevant to the discovery and 
translational application of mRNA expression biomarkers and take into account of the 
variation of analytical factors, to extensively investigate the concordance between FFPE 
and FF RNA-seq data, as well as the effects of pre-analytical factors of RNA-seq on such 
concordance (Figure 1.1). We found in this study that capture sequencing, rather than 
FFPE conditioning, is the dominant determinant for the variation of RNA-seq data. We 
also successfully identified one FFPE library preparation protocol that can generate 
RNA-seq data consistently highly concordant with and being least deviated from any 
types of non-capture sequenced FF references. The computational methods we applied in 
this study will be useful for other comparative analysis aiming to study the influences of 
pre-analytical factors of RNA-seq on mRNA expression data quality. 
In the second project, we were challenged by estimating second primary cancer-
specific penetrance of germline TP53 mutation from individuals with missing genotype 
information. Justified by careful preliminary analysis of the real data, we proposed a 
Bayesian semiparametric recurrent events model based on NHPP in order to reflect the 
age-dependent and time-varying nature of the cancer occurrence rate in LFS study. 
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Following the idea of Shin et. al(80), we defined the familywise likelihood by averaging 
individual likelihoods within the family over the missing genotypes. This is possible 
since the exact distribution of missing genotypes is available according to the Mendelian 
law of inheritance. The familywise likelihood can minimize the efficiency loss due to the 
missing genetic information by utilizing family structure. We therefore developed the 
ascertainment corrected familywise likelihood for the proposed NHPP model and 
estimated the penetrance parameters via the MCMC algorithm. The MPC-specific 
penetrance we provided here for LFS study is stratified not only by genotype and gender, 
but also by the interaction of previous primary cancer diagnosis and genotype, as well as 
the age of first primary cancer diagnosis. Our penetrance estimates have a reliable cancer 
risk prediction performance on an independent dataset when comparing to that of the 
penetrance estimated by KM method. To the best of our knowledge, this is the first time 
that a high-resolution MPC-specific penetrance is reported and its cancer risk prediction 
performance is thoroughly evaluated.   
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4.2 Future Research 
My dissertation is still left with a few possible extensions. For the FFPE RNA-seq 
project, we focused our comparative analysis on mRNA expression profiling. In future 
research, we may consider extending the analysis to other RNA species, like long non-
coding RNA and microRNA, as they play important regulatory role in human cancer and 
have potential utility as cancer prognosis biomarkers(91-96). Also, in future the analysis 
should cover other aspects of detecting aberrant transcription in human cancer, such as 
gene fusion and alternative splicing analysis, as increasing evidences suggest their utility 
in cancer diagnostics and prognosis(10). For example, the detection of RUNX1-RUNX1T1 
fusion has been suggested by World Health Organization as an alternative diagnostic 
method acute myeloid leukemia(97), and the TMPRSS2-ERG fusion has been shown 
associated with prostate cancer prognosis(98). Future work should be focused on 
incorporating these aspects of analysis to achieve a more comprehensive assessment of 
FFPE RNA-seq data quality.      
For the multiple primary cancers penetrance estimation, we limited our analysis up to the 
second cancer diagnosis, as there are no mutation non-carriers with more than two 
primary cancers during follow-up in the training data. Our model is flexible to generate 
penetrance for third or fourth primary cancer if in future we have sufficient number of 
individuals with a history of two or more cancers. Also, we can easily modify our model 
to incorporate the treatment information to account the effects of radiotherapy or tissue-
resection on future cancer occurrence rate. Finally, our model does not consider 
competing risk from different types of primary cancers, but in LFS MPC patients do 
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usually exhibit multiple types of cancers, such as sarcoma, leukemia and brain tumor. 
Future research should extend the current model to take into account this competing risk.       
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Appendix 
Appendix A: Computation of IPCW Kendall’s ! 
Let (!!, !!) and  (!!, !!) be two independent realizations of (!,!!), the first and the 
second gap time, and let !!" = !! !! − !! !! − !!! > 0 − !!!{ !! − !! !! − !!! <0} indicate the concordance/discordant status of the pair, the Kendall’s ! (99) can be 
estimated from uncencored bivariate data { !! ,!! , ! = 1,⋯ ,!} by !2 !! !!"!!!  
In the presence of censoring events  (!!, !!) related to the two gap times, respectively, 
the estimation of ! can only be based on orderable pairs. Let one observation be denoted 
as (!,!, !! , !!), where ! = min !,!! , ! = min !,!! , !! = I!(X < !!) and !! = I!(Y < !!). Oakes et.al showed that the pair (!, !) is orderable if {!!" < !!!!" ,!!" <! !!"), where !!" = min!(!! ,!!), !!" = min!(!! ,!!), !!!" = min!(!!! ,!!!) !!!" =min!(!!! ,!!!) (100). Let !!" be the indicator of this event, and !!" be an estimator of the 
probability of being orderable !!" = Pr !! > !!"; !!! > !!" !!" ,!!"), Lakhal-Chaieb 
et.al proposed the weighted estimate as  
!! = ! !!"!!"!!!
!! !!"!!"!!"!!!  
To identify orderable pairs and estimate the corresponding !!", Lakhal-Chaieb et.al 
showed that !!" can be reduced to that !! and !! are uncensored, !!" is observed, and that {!!! > !! + !!!"; !!!! > !! + !!!"}. The conditional probability of a pair being orderable 
is then  
! ! 91 
!!" = Pr !!! > !! + !!"; !!!! > !! + !!"|!!! ,!! ,!!"= !(!! + !!!")×!!(!! + !!!")  
The probability is estimated by  !!" = !(!! + !!!")×!!(!! + !!!") 
where ! ∙  is the Kaplan-Meier estimator of ! ∙  based on { !! + !! , 1− !!!! , ! =1,⋯ ,!}. The standard error of the kendall’s ! is estimated by the Jackknife.  
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Appendix B: An example of using peeling algorithm to calculate familywise 
likelihood 
Figure 3.7 shows an example of a hypothetical family with three generations. Assume 
that the genotype is known for the 4th individual and unknown for all other members, or !!"#! = (!!,!!,!!,!!,!!,!!). Let !! = (ℎ!,⋯ , ℎ!) denotes the cancer phenotype for 
the family, we want to calculate the familywise likelihood by marginalizing out !!"#, ! ! !! = ! ! !,!!"# !! = ! !(!|!!"#,!!)!(!!"#|!!)!!"#!!"#  
The Elston-Stewart algorithm exploits the family structure by Mendelian inheritance 
property and introduces a “peeling” method, which rewrites the likelihood as,  = !(ℎ!|!!)!(ℎ!|!!)!(!!|!!) !(ℎ!|!!)!(!!|!!,!!) !(ℎ!|!!)!(!!|!!,!!)!!!!!! !(ℎ!|!!)!(!!|!!) !(ℎ!|!!)!(!!|!!,!!) !(ℎ!|!!)!(!!|!!,!!)!!!!!!
 
 
Note that in our example, the partial likelihood of upper part of the family (anterior) can 
be evaluated separately from that of the lower part of the family (posterior) given the 
genotype of the 4th individual (pivot element), or Anterior ⊥ Posterior | Pivot element. 
Also, within a nuclear family the likelihood for some members can be evaluated 
separately (e.g.: the 6th and 7th individual). This is based on the Mendelian inheritance 
property that a child’s genotype only depends on his parents’ genotypes. The computation 
complexity is then reduced by the algorithm from !!(3!) to !! !"#$(!)  if TP53 has 
three genotypes.  
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Figure Appendix B: A hypothetical pedigree for illustrating likelihood calculation using 
the Elston- Stewart algorithm. The family consists of three generations. The circle 
indicates the female member while the square indicates the male. In this example, the 
genotype is assumed unknown for every members except the 4th individual.  
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